These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38665214)

  • 1. ICH S1 prospective evaluation study: weight of evidence approach to predict outcome and value of 2-year rat carcinogenicity studies. A report from the regulatory authorities subgroup.
    Bourcier T; McGovern T; Cavaliero T; Ebere G; Nishikawa A; Nishimura J; Ogawa K; Pasanen M; Vespa A; Van der Laan JW
    Front Toxicol; 2024; 6():1353783. PubMed ID: 38665214
    [No Abstract]   [Full Text] [Related]  

  • 2. ICH S1 prospective evaluation study and weight of evidence assessments: commentary from industry representatives.
    Vahle JL; Dybowski J; Graziano M; Hisada S; Lebron J; Nolte T; Steigerwalt R; Tsubota K; Sistare FD
    Front Toxicol; 2024; 6():1377990. PubMed ID: 38845817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.
    Bassan A; Steigerwalt R; Keller D; Beilke L; Bradley PM; Bringezu F; Brock WJ; Burns-Naas LA; Chambers J; Cross K; Dorato M; Elespuru R; Fuhrer D; Hall F; Hartke J; Jahnke GD; Kluxen FM; McDuffie E; Schmidt F; Valentin JP; Woolley D; Zane D; Myatt GJ
    Front Toxicol; 2024; 6():1370045. PubMed ID: 38646442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum.
    Stalford SA; Cayley AN; de Oliveira AAF
    Regul Toxicol Pharmacol; 2021 Dec; 127():105071. PubMed ID: 34737134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Forum.
    Peden WM
    Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.
    Morton D; Sistare FD; Nambiar PR; Turner OC; Radi Z; Bower N
    Toxicol Pathol; 2014 Jul; 42(5):799-806. PubMed ID: 23965809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing human carcinogenicity risk of agrochemicals without the rodent cancer bioassay.
    Goetz A; Ryan N; Sauve-Ciencewicki A; Lord CC; Hilton GM; Wolf DC
    Front Toxicol; 2024; 6():1394361. PubMed ID: 38933090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.
    van der Laan JW; Kasper P; Silva Lima B; Jones DR; Pasanen M
    Crit Rev Toxicol; 2016 Aug; 46(7):587-614. PubMed ID: 27116466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the Carcinogenic Potential of Human Pharmaceuticals Using Repeated Dose Toxicity Data and Their Pharmacological Properties.
    van der Laan JW; Buitenhuis WH; Wagenaar L; Soffers AE; van Someren EP; Krul CA; Woutersen RA
    Front Med (Lausanne); 2016; 3():45. PubMed ID: 27790617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation.
    Monro AM; MacDonald JS
    Drug Saf; 1998 May; 18(5):309-19. PubMed ID: 9589843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Notice; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Mar; 78(52):16681-4. PubMed ID: 23530289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
    Contrera JF; DeGeorge JJ
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
    Galloway SM
    Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Strategy to Predict Carcinogenicity of Antiparasitics Based on a Combination of DNA Lesions and Bacterial Mutagenicity Tests.
    Liu Q; Lei Z; Zhu F; Ihsan A; Wang X; Yuan Z
    Front Public Health; 2017; 5():288. PubMed ID: 29170735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-neoplastic lesions found only in the two-year bioassays but not in shorter toxicity studies of rats.
    Nonaka M; Amakasu K; Saegusa Y; Naota M; Nishimura T; Ogawa K; Nishikawa A
    Regul Toxicol Pharmacol; 2017 Jun; 86():199-204. PubMed ID: 28288808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.